PKO Investment Management Joint Stock Co Takes $7.69 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PKO Investment Management Joint Stock Co acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,800 shares of the biopharmaceutical company's stock, valued at approximately $7,693,000. Regeneron Pharmaceuticals accounts for approximately 1.0% of PKO Investment Management Joint Stock Co's investment portfolio, making the stock its 18th largest position.

A number of other hedge funds have also recently made changes to their positions in REGN. Pinney & Scofield Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Avalon Trust Co purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN traded down $112.15 during midday trading on Friday, reaching $493.24. 6,307,887 shares of the company's stock were exchanged, compared to its average volume of 829,463. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $53.25 billion, a PE ratio of 12.89, a P/E/G ratio of 2.34 and a beta of 0.43. The business's 50-day moving average price is $584.25 and its 200 day moving average price is $665.66. Regeneron Pharmaceuticals, Inc. has a 1-year low of $485.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $9.55 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on REGN. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. Bernstein Bank dropped their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $600.00 to $700.00 in a research note on Wednesday, May 14th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $700.00 to $580.00 in a research note on Friday. Finally, Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $874.56.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.